Skip to main content

Myriad Genetics Said Q1 Losses Widened as Spending Overpowered Strong Revenue Growth

NEW YORK, Nov. 6 - Myriad Genetics yesterday said that greater spending in its fiscal first quarter overpowered strong revenue growth to widen net loss.

 

Total receipts in the period ended Sept. 30 increased to $15.5 million from $13.2 million on year ago. Driving that growth were receipts from Myriad's predictive medicine divisions, which grew by $2.2 million, or 43 percent, on sales of the BRACAnalysis breast cancer test and the Colaris products for colon and uterine cancer.

 

However, revenue from combined research activities in the current first quarter dipped to $7.6 million from $7.7 million last year as Myriad shifted more of its focus to internal drug-development programs.

 

R&D spending in the quarter increased 33 percent to $10.9 million. Myriad said the increase was due mainly to costs associated with developing its therapeutic pipeline, which contains 15 drug candidates.

 

First-quarter SG&A spending also jumped by 37 percent to $7.7 million, reflecting an unspecified increase in sales force, Myriad said.

 

Consequently, net loss for the first quarter 2002 swelled to $5.3 million, or $.22 per share, from $1.2 million, or $.05 per share, year over year, Myriad said.

 

The company said it had roughly $103.7 million in cash and marketable investment securities as of Sept. 30.

 

Click here for more information.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.